Clinical Trials Logo

Clinical Trial Summary

Giant cell arteritis (GCA) is the most frequent vascularitis after 50 years of age The investigators recently showed that GCA was accompanied by an elevation in Th1 and Th17 response [1]. Even though a quantitative deficit in regulatory TL (Treg) was shown, there are to date no data concerning their precise phenotypic and functional characteristics and notably their ability to inhibit Th1 and Th17 polarisation. The hypothesis of the investigator is that, in GCA, there is quantitative and above all functional deficit of Treg. Recently, progress has been made in the identification of Treg with new markers (CD39), which will make it possible to better identify and to study their specific functions. In this study the phenotypic and functional characteristics of Treg in GCA will be analysed. Better understanding of the role des Treg in GCA should lead to better-targeted treatments for patients with GCA, notably via the blockage of cytokines that inhibit the differentiation and/or function of Treg.

The study is classified interventional because a lot of blood samples are taken.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02857192
Study type Interventional
Source Centre Hospitalier Universitaire Dijon
Contact
Status Completed
Phase N/A
Start date October 5, 2015
Completion date March 25, 2019

See also
  Status Clinical Trial Phase
Completed NCT02065297 - Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Completed NCT02158208 - Study of the T CD8 Immune Response in Horton's Disease
Terminated NCT02955147 - Ustekinumab for the Treatment of Giant Cell Arteritis Phase 1/Phase 2
Active, not recruiting NCT04390126 - COVID-19 Related Lockdown Effects On Chronic Diseases